Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2009

View Archived Issues

Bristol-Myers Squibb claims DGAT-1 inhibitors for the treatment of obesity

Takeda describes novel AR antagonists for cancer therapy

Yakult Honsha discloses novel MMP inhibitors for cancer therapy

Novel GK activators for the treatment of diabetes presented by Roche

Intra-Cellular Therapies reports results of a phase I PET study for ITI-007

European CHMP recommends approval of Novartis's MAA for Menveo vaccine

Insulin secretion stimulators in development Merck KGaA for type 2 diabetes therapy

Athersys enters into global agreement with Pfizer to develop MultiStem for IBD

CombinatoRx and Neuromed close merger

CPEX completes enrollment in phase IIa Nasulin trial

Michael J. Fox Foundation awards grant for dyskinesia treatment development

Soligenix initiates phase I/II SGX-201 trial for acute radiation enteritis

FDA grants TessArae Emergency Use Authorization for TessArray assay

PDL and Lilly sign license agreement for teplizumab and other anti-CD3 molecules

TG-101348 reduces JAK2 V617F allele burden in phase I myelofibrosis trial

BHQ-880 shown to be safe in combination with zoledronic acid and MM therapy

GP2/GM-CSF peptide vaccine may prevent breast cancer recurrence

Fluticasone furoate nasal spray may be beneficial in children with otitis media

Vadimezan added to taxane-containing regimens evaluated in mouse breast cancer models

Clinuvel reports results from phase III trial of afamelanotide in erythropoietic protoporphyria

Neurocrine to initiate clinical development of VMAT2 inhibitor NBI-98854

4SC initiates three clinical trials in oncology pipeline

Idera reports interim results from phase I clinical trial of IMO-2125 in chronic HCV

Leo Pharma reports results from phase III clinical trials of PEP-005

NicOx submits MAA to EMEA for anti-inflammatory drug naproxcinod

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...